Pfizer and BioNTech will conduct three simultaneous trials in adults to determine if an omicron-specific vaccine is more effective than current shots.
Author: Karen Weintraub, USA TODAY
Beyond Aduhelm: Why experts have never felt more optimistic about Alzheimer’s treatments
Even as the controversial new drug Aduhelm offers hope for those with Alzheimer’s, researchers are exploring new kinds of treatment approaches.
Treatment shortages, packed hospitals: Why at-risk adults should be on COVID alert
As omicron spreads, there’s a shortage of COVID-19 treatments, drugs and hospital beds, making those at high-risk for illness even more vulnerable.
‘My dad’s a fighter’: Man’s recovery exceeding expectations after receiving heart from genetically modified pig
Dave Bennett, 57, who received the first heart transplant from a genetically modified pig, is breathing on his own, and speaking with a quiet voice.
First pig-to-human heart transplant offers hope for thousands in need of organs
The breakthrough by doctors at the University of Maryland offers hope for those who languish on organ transplant waitlists.
Pfizer COVID-19 shot won’t be ready for youngest kids for months: ‘Might be a three-dose vaccine’
The lower dose given to 2- to 5-year-olds hasn’t produced the necessary immune protection in early tests, according to Pfizer.
Skeptics doubted vaccines long before COVID, despite health gains
Have questions about the safety of vaccines for kids? Welcome to a long history of those who have asked if getting sick is more dangerous than a shot.
Good news about omicron: It may pass quickly, pose small threat to vaccinated, experts say
Because omicron is so contagious, it may not be around for long, and people who are fully vaccinated tend to see few symptoms, experts say.
Trailblazing gene therapy offers promise of curing rare diseases before they take hold
in the coming years, scientists hope to end a number of illnesses that have caused misery for generations.
New COVID treatments are coming. Will they be here in time to combat the omicron onslaught?
New antiviral COVID-19 treatments are coming but getting enough supply to fight the omicron variant surge is a concern.